Back to search results

Biospecimen Collection Study for Solid Tumors, Healthy Donors, and COVID-19 Donors

This study is collecting blood samples (biospecimens) from adults with solid tumors, healthy adults, and COVID-19 donors. Researchers want to see if they can successfully collect, grow, and select specific immune cells called T lymphocytes from these blood samples. They are particularly interested in T cells that have certain markers, PD-1 and CTLA4, on their surface. The goal is to evaluate if these selected T cells can effectively fight against tumor cells in a lab setting. This is an observational study, meaning you would not receive any intervention or treatment. The study aims to enroll 1500 participants, and its current status is unclear.

Study design
This is an observational study aiming to enroll 1500 participants, including adults with solid tumors, healthy adults, and COVID-19 donors.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00571389

A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

Recruiting
Not specifiedAges 5+Observational
BioCytics, Inc.
~1,500 participants
Updated 2026-03-18 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring

A primary outcome measure isn't published for this study.

Conditions

Solid Tumor, Adult
Healthy Donors
COVID-19 Donors

Explore related trials

COVID-19 InfectionSolid Neoplasm

NCT00571389

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Carolina BioOncology Institute

    Huntersville, North Carolinastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

John Powderly, MD
704-947-6599
Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

ECOG Performance Status of 0 or 1 (see Appendix 2)
WBC ≥2000/μL
Neutrophils ≥1000/μL
Platelets ≥100x103/μL
Hemoglobin ≥9 g/dL
Creatinine ≤2.5 x ULN
AST ≤2.5 x ULN without, and ≤ 5 x ULN with hepatic metastases
Bilirubin ≤2 x ULN (except patients with Gilbert's syndrome, who must have total bilirubin ≤ 3.0 mg/dL)
Negative urine pregnancy test for women of childbearing potential
History of autoimmune disease or inflammatory disorder considered clinically stable by the Principal Investigator or treating physician's discretion.
Suspected or diagnosed COVID-19 disease by laboratory test, whether in the acute, sub-acute or convalesced state.
Must be ≥ 18 years of age.
WBC ≥2000/μL
Neutrophils ≥1000/μL
Platelets ≥100x103/μL
Hemoglobin ≥9 g/dL
Creatinine ≤2.5 x ULN
AST ≤2.5 x ULN
Bilirubin ≤2 x ULN (except patients with Gilbert's syndrome, who must have total bilirubin ≤ 3.0 mg/dL)
Negative urine pregnancy test for women of childbearing potential